VRK2 Polyclonal Antibody, APC-Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-12780R-APC-Cy5.5-100uL |
| Product Name | VRK2 Polyclonal Antibody, APC-Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat, Chicken |
| Specifications | |
| Conjugation | APC-Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VRK2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 7444 |
| Swiss Prot | Q86Y07 |
| Subcellular location | Cell membrane |
| Synonyms | Serine/threonine-protein kinase VRK2; VRK2; Vaccinia-related kinase 2 |
| Background | Serine/threonine kinase that regulates several signal transduction pathways. Isoform 1 modulates the stress response to hypoxia and cytokines, such as interleukin-1 beta (IL1B) and this is dependent on its interaction with MAPK8IP1, which assembles mitogen-activated protein kinase (MAPK) complexes. Inhibition of signal transmission mediated by the assembly of MAPK8IP1-MAPK complexes reduces JNK phosphorylation and JUN-dependent transcription. Phosphorylates 'Thr-18' of p53/TP53, histone H3, and may also phosphorylate MAPK8IP1. Phosphorylates BANF1 and disrupts its ability to bind DNA and reduces its binding to LEM domain-containing proteins. Downregulates the transactivation of transcription induced by ERBB2, HRAS, BRAF, and MEK1. Blocks the phosphorylation of ERK in response to ERBB2 and HRAS. Can also phosphorylate the following substrates that are commonly used to establish in vitro kinase activity: casein, MBP and histone H2B, but it is not sure that this is physiologically relevant. Isoform 2 phosphorylates 'Thr-18' of p53/TP53, as well as histone H3. Reduces p53/TP53 ubiquitination by MDM2, promotes p53/TP53 acetylation by EP300 and thereby increases p53/TP53 stability and activity. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is VRK2 Polyclonal Antibody, APC-Cy5.5 Conjugated (BS-12780R-APC-CY5-5) validated for, and at what dilution?
BS-12780R-APC-CY5-5 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does VRK2 Polyclonal Antibody, APC-Cy5.5 Conjugated (BS-12780R-APC-CY5-5) react with?
Tested reactivity: Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Human, Rat, Chicken.
How should BS-12780R-APC-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise VRK2 Polyclonal Antibody, APC-Cy5.5 Conjugated (BS-12780R-APC-CY5-5)?
KLH conjugated synthetic peptide derived from human VRK2
What are the excitation and emission wavelengths of the APC-Cy5.5 conjugate (BS-12780R-APC-CY5-5)?
APC-Cy5.5 on BS-12780R-APC-CY5-5: excitation / emission 650nm/694nm.